A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

Overview

About this study

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Age ≥18
* Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Exclusion Criteria:

* Metal implants that are not suitable for MRI
* Inability or unwillingness of individual to give written informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

 

Eligibility last updated 08/06/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Claire Raphael

Open for enrollment

Contact information:

Diana Albers

(507) 255-6884

Albers.Diana2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597184

Mayo Clinic Footer